EBMT 2024 | Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses relapse incidence in patients with acute myeloid leukemia (AML) who have received allogeneic stem cell transplantation (alloSCT) in the first complete remission (CR1). Post-transplant cyclophosphamide (PTCy) reduces graft-versus-host disease (GvHD), causing concerns that this would reduce the graft-versus-leukemia (GvL) effect and cause higher relapse rates. However, Prof. Nagler mentions a study that reveals no differences in relapse rates between patients treated with PTCy versus other GvHD prophylaxis regimens. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
